AR054506A1 - Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes - Google Patents

Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes

Info

Publication number
AR054506A1
AR054506A1 ARP060102811A ARP060102811A AR054506A1 AR 054506 A1 AR054506 A1 AR 054506A1 AR P060102811 A ARP060102811 A AR P060102811A AR P060102811 A ARP060102811 A AR P060102811A AR 054506 A1 AR054506 A1 AR 054506A1
Authority
AR
Argentina
Prior art keywords
compositions
images
iron oxide
oxide particles
magnetic iron
Prior art date
Application number
ARP060102811A
Other languages
English (en)
Inventor
Andreas Briel
Bernhard Gleich
Jurgen Weizenecker
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR054506A1 publication Critical patent/AR054506A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/418—Evaluating particular organs or parts of the immune or lymphatic systems lymph vessels, ducts or nodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/0515—Magnetic particle imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/415—Evaluating particular organs or parts of the immune or lymphatic systems the glands, e.g. tonsils, adenoids or thymus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/416—Evaluating particular organs or parts of the immune or lymphatic systems the spleen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1836—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Iron (AREA)
  • Soft Magnetic Materials (AREA)

Abstract

La presente se refiere a complejos que contienen partículas magnéticas de oxido de hierro en una cobertura aceptable para uso farmacéutico, donde dichas partículas tienen un diámetro entre 20nm y 1mm con una proporcion entre el diámetro total de partícula y el diámetro del nucleo menor de 6 y al uso de dichos complejos en el diagnostico por imágenes con partículas magnéticas (MPI). Se refiere en particular el uso de dichas composiciones en los exámenes del tracto gastrointestinal, del sistema vascular cardíaco y componentes craneanos, en el diagnostico de arteriosclerosis, infartos, y tumores y metástasis, por ejemplo el sistema linfático.
ARP060102811A 2005-06-29 2006-06-29 Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes AR054506A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05014059A EP1738774A1 (de) 2005-06-29 2005-06-29 Magnetische Eisenoxidpartikel enthaltende Zusammensetzungen und deren Verwendung in bildgebenden Verfahren

Publications (1)

Publication Number Publication Date
AR054506A1 true AR054506A1 (es) 2007-06-27

Family

ID=35432718

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102811A AR054506A1 (es) 2005-06-29 2006-06-29 Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes

Country Status (12)

Country Link
EP (2) EP1738774A1 (es)
JP (1) JP5366542B2 (es)
CN (1) CN101378785B (es)
AR (1) AR054506A1 (es)
BR (1) BRPI0611755A2 (es)
DO (1) DOP2006000153A (es)
PA (1) PA8684301A1 (es)
PE (1) PE20070204A1 (es)
RU (1) RU2417104C2 (es)
TW (1) TW200711664A (es)
UY (1) UY29644A1 (es)
WO (1) WO2007000350A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112133553A (zh) * 2020-10-30 2020-12-25 福州大学 一种水基磁流体的连续制备方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1738773A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzung und deren Vervendung in bildgebenden Verfahren
JP5353004B2 (ja) * 2007-01-05 2013-11-27 国立大学法人東京工業大学 球形フェライトナノ粒子の製造方法
JP5100212B2 (ja) 2007-06-15 2012-12-19 株式会社東芝 磁性微粒子イメージング装置、検出コイル配設方法および磁束検出装置
BRPI0910403A8 (pt) * 2008-04-03 2015-11-10 Koninklijke Philips Electronics Nv Uso de um agente traçador de mpi, e, método para o monitoramento visual de um produto biocompatível.
US20110316526A1 (en) 2009-03-09 2011-12-29 Koninklijke Philips Electronics N.V. Arrangement and method for measuring a magnetic material in a region of action
WO2010128418A1 (en) 2009-05-08 2010-11-11 Koninklijke Philips Electronics N.V. Arrangement and method for heating of a magnetic material
CN102686518B (zh) * 2009-11-20 2015-07-29 户田工业株式会社 磁性氧化铁微粒粉末、含有磁性颗粒的水分散体及其制造方法
WO2012007871A1 (en) 2010-07-13 2012-01-19 Koninklijke Philips Electronics N.V. System and method for generating a system function for use in the reconstruction of images
CN102092795B (zh) * 2010-12-11 2015-11-18 上海纳米技术及应用国家工程研究中心有限公司 有机高分子修饰的四氧化三铁多级球的制备方法
CA2778561C (en) * 2011-05-31 2020-10-13 Ghandi, Khashayar Magnetic nanocomposite material and processes for the production thereof
EP2647389A1 (en) 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
US20150374855A1 (en) 2013-02-20 2015-12-31 Topass Gmbh Oral contrast medium for the diagnostic investigation of the gastrointestinal tract by means of mpi
CZ2014451A3 (cs) * 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
RU2582870C2 (ru) * 2014-07-16 2016-04-27 Акционерное общество "Государственный Ордена Трудового Красного Знамени научно-исследовательский институт химии и технологии элементоорганических соединений" (АО "ГНИИХТЭОС") Способ получения ферромагнитных металлических наночастиц с твердой изоляционной оболочкой
DE102014019388A1 (de) * 2014-12-29 2016-06-30 Susanne Wagner Arzneimittel auf der Basis von Maghämit zur gleichzeitigen Reduzierung der gastrointestinalen Natriumresorption und Phosphatresorption
JP2019151552A (ja) * 2016-07-12 2019-09-12 名糖産業株式会社 磁性粒子
DE102017108737A1 (de) 2017-04-24 2018-10-25 Universität Zu Lübeck Verfahren und Vorrichtung zur Herstellung von magnetischen Nanopartikeln
CA3106672C (en) 2018-07-19 2024-04-02 Beckman Coulter, Inc. Magnetic particles
CN111979794B (zh) * 2020-07-31 2022-01-04 盐城工学院 一种提高织物天然染料碱性浴染色效果的功能改性方法
CN114028423B (zh) * 2021-12-13 2023-05-23 广东粤港澳大湾区国家纳米科技创新研究院 修饰的纳米氧化铁在制备预防和/或治疗炎性肠病的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916539A (en) * 1993-03-02 1999-06-29 Silica Gel Ges. M.B.H. Superparamagnetic particles, process for producing the same and their use
DE59706019D1 (de) * 1996-08-05 2002-02-21 Schering Ag Vorrichtung und verfahren zur abtrennung magnetischer materialien aus pharmazeutischen zubereitungen, deren ausgangs- oder zwischenprodukten sowie mit hilfe dieser vorrichtung hergestellte mittel
DE10151778A1 (de) * 2001-10-19 2003-05-08 Philips Corp Intellectual Pty Verfahren zur Ermittlung der räumlichen Verteilung magnetischer Partikel
CN1774200B (zh) * 2003-04-15 2010-07-28 皇家飞利浦电子股份有限公司 对检测区域内的状态变量进行空间解像测定的装置及方法
EP1615558B1 (en) * 2003-04-15 2012-02-22 Philips Intellectual Property & Standards GmbH Method for the spatially resolved determination of physical, chemical and biological properties or state variables
WO2005046733A1 (en) * 2003-11-17 2005-05-26 Philips Intellectual Property & Standards Gmbh Contrast agent for medical imaging techniques and usage thereof
EP1738773A1 (de) * 2005-06-29 2007-01-03 Schering AG Magnetische Eisenoxidpartikel enthaltende Zusammensetzung und deren Vervendung in bildgebenden Verfahren

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112133553A (zh) * 2020-10-30 2020-12-25 福州大学 一种水基磁流体的连续制备方法

Also Published As

Publication number Publication date
JP2008546630A (ja) 2008-12-25
JP5366542B2 (ja) 2013-12-11
RU2008103202A (ru) 2009-08-10
BRPI0611755A2 (pt) 2012-04-17
EP1738774A1 (de) 2007-01-03
UY29644A1 (es) 2007-01-31
EP1898959A1 (en) 2008-03-19
PE20070204A1 (es) 2007-03-02
RU2417104C2 (ru) 2011-04-27
PA8684301A1 (es) 2007-01-17
DOP2006000153A (es) 2007-09-15
WO2007000350A1 (en) 2007-01-04
CN101378785B (zh) 2013-01-23
CN101378785A (zh) 2009-03-04
TW200711664A (en) 2007-04-01

Similar Documents

Publication Publication Date Title
AR054506A1 (es) Composiciones que contienen particulas magneticas de oxido de hierro y uso de dichas composiciones en metodos de diagnostico por imagenes
DOP2006000154A (es) Composiciones que contienen partículas magnéticas de óxido de hierro, y uso de dichas composiciones en métodos de diagnóstico por imágenes
Zheng et al. Highly integrated nano-platform for breaking the barrier between chemotherapy and immunotherapy
Richard et al. Noncovalent functionalization of carbon nanotubes with amphiphilic Gd3+ chelates: toward powerful T1 and T2 MRI contrast agents
Mukherjee et al. The yin and yang of imaging tumor associated macrophages with PET and MRI
Hahn et al. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives
Cai et al. Near‐infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases
Weng et al. Toxicological risk assessments of iron oxide nanocluster-and gadolinium-based T1MRI contrast agents in renal failure rats
Georgiadou et al. Octadecylamine-mediated versatile coating of CoFe2O4 NPs for the sustained release of anti-inflammatory drug naproxen and in vivo target selectivity
Chi et al. Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma
US20230330275A1 (en) Fap-targeted radiopharmaceuticals and imaging agents, and uses related thereto
Tu et al. Multimodality PET/MRI agents targeted to activated macrophages
Yu et al. In depth analysis of apoptosis induced by silica coated manganese oxide nanoparticles in vitro
CN103007303A (zh) 核-壳型三模态纳米造影剂、其制备方法及应用
Perera et al. Nanoparticles of the novel coordination polymer KBi (H2O) 2 [Fe (CN) 6]· H2O as a potential contrast agent for computed tomography
Cormode et al. Nanoparticle contrast agents for CT: their potential and the challenges that lie ahead
Zhang et al. DNA-functionalized liposomes in vivo fusion for NIR-II/MRI guided pretargeted ferroptosis therapy of metastatic breast cancer
Yin et al. Epigallocatechin gallate based magnetic gold nanoshells nanoplatform for cancer theranostic applications
JP2011519367A5 (es)
Zhang et al. Iron-Based Nanovehicle Delivering Fin56 for Hyperthermia-Boosted Ferroptosis Therapy Against Osteosarcoma
ES2541787A1 (es) Compuestos y composiciones que comprenden nanotubos de carbono y compuestos de formula (I) y su uso como agentes de contraste
WO2018051289A3 (en) Novel liposomal gadolinium (gd) contrast agent "nmrx" for t1-mri
Mirpour et al. Clinical stem cell imaging and in vivo tracking
Ji et al. Tracking of Intestinal Probiotics In Vivo by NIR-IIb Fluorescence Imaging
Khayat et al. Fibromatose mammaire: corrélations anatomo-radio-cliniques et revue de la littérature

Legal Events

Date Code Title Description
FA Abandonment or withdrawal